EZH2 and cancer: This study reveals that inhibition of EZH2 activity may be a compelling therapeutics for a spectrum of cancers with genetic alterations conferring a proliferative dependency on EZH2 enzymatic activity despite EZH2 itself is not genetically changed in the cancers.